source
- Biogen pushing tau drug forward despite Alzheimer’s study failureOne of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.
- Understanding MET Alterations in Non‑Small Cell Lung Cancer and Emerging Targeted Treatment OptionsThe article outlines the primary MET alterations observed in non‑small cell lung cancer, focusing on gene amplification and exon 14 skipping mutations. It explains that these MET changes frequentl…